vs
Side-by-side financial comparison of MARINE PRODUCTS CORP (MPX) and Twist Bioscience Corp (TWST). Click either name above to swap in a different company.
Twist Bioscience Corp is the larger business by last-quarter revenue ($103.7M vs $64.6M, roughly 1.6× MARINE PRODUCTS CORP). MARINE PRODUCTS CORP runs the higher net margin — 3.7% vs -29.4%, a 33.1% gap on every dollar of revenue. On growth, MARINE PRODUCTS CORP posted the faster year-over-year revenue change (35.0% vs 16.9%). MARINE PRODUCTS CORP produced more free cash flow last quarter ($4.1M vs $-34.8M).
West Marine is an American company based in Fort Lauderdale, Florida, which operates a chain of boating supply and fishing retail stores. The company has 247 retail stores in North America. West Marine also runs Blue Future a non profit organization. West Marine's flagship store is in Fort Lauderdale. Opened on November 11, 2011, the store is the company's largest at over 50,000 square feet.
Twist Bioscience is a public biotechnology company based in South San Francisco that manufactures synthetic DNA and DNA products for customers in a wide range of industries. Twist was founded in 2013 by Emily Leproust, Bill Banyai, and Bill Peck.
MPX vs TWST — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $64.6M | $103.7M |
| Net Profit | $2.4M | $-30.5M |
| Gross Margin | 19.6% | 52.0% |
| Operating Margin | 5.8% | -31.7% |
| Net Margin | 3.7% | -29.4% |
| Revenue YoY | 35.0% | 16.9% |
| Net Profit YoY | -44.6% | 3.4% |
| EPS (diluted) | $0.07 | $-0.50 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $64.6M | $103.7M | ||
| Q3 25 | $53.1M | — | ||
| Q2 25 | $67.7M | — | ||
| Q1 25 | $59.0M | — | ||
| Q4 24 | $47.8M | — | ||
| Q3 24 | $49.9M | — | ||
| Q2 24 | $69.5M | — | ||
| Q1 24 | $69.3M | — |
| Q4 25 | $2.4M | $-30.5M | ||
| Q3 25 | $2.6M | — | ||
| Q2 25 | $4.2M | — | ||
| Q1 25 | $2.2M | — | ||
| Q4 24 | $4.3M | — | ||
| Q3 24 | $3.4M | — | ||
| Q2 24 | $5.6M | — | ||
| Q1 24 | $4.6M | — |
| Q4 25 | 19.6% | 52.0% | ||
| Q3 25 | 19.2% | — | ||
| Q2 25 | 19.1% | — | ||
| Q1 25 | 18.6% | — | ||
| Q4 24 | 19.2% | — | ||
| Q3 24 | 18.4% | — | ||
| Q2 24 | 18.9% | — | ||
| Q1 24 | 20.2% | — |
| Q4 25 | 5.8% | -31.7% | ||
| Q3 25 | 5.4% | — | ||
| Q2 25 | 7.1% | — | ||
| Q1 25 | 4.4% | — | ||
| Q4 24 | 7.7% | — | ||
| Q3 24 | 7.2% | — | ||
| Q2 24 | 8.3% | — | ||
| Q1 24 | 7.6% | — |
| Q4 25 | 3.7% | -29.4% | ||
| Q3 25 | 5.0% | — | ||
| Q2 25 | 6.1% | — | ||
| Q1 25 | 3.7% | — | ||
| Q4 24 | 8.9% | — | ||
| Q3 24 | 6.8% | — | ||
| Q2 24 | 8.0% | — | ||
| Q1 24 | 6.6% | — |
| Q4 25 | $0.07 | $-0.50 | ||
| Q3 25 | $0.07 | — | ||
| Q2 25 | $0.12 | — | ||
| Q1 25 | $0.06 | — | ||
| Q4 24 | $0.13 | — | ||
| Q3 24 | $0.10 | — | ||
| Q2 24 | $0.14 | — | ||
| Q1 24 | $0.13 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $197.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $125.0M | $456.1M |
| Total Assets | $147.2M | $638.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $197.9M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $125.0M | $456.1M | ||
| Q3 25 | $126.3M | — | ||
| Q2 25 | $127.2M | — | ||
| Q1 25 | $126.4M | — | ||
| Q4 24 | $129.0M | — | ||
| Q3 24 | $128.8M | — | ||
| Q2 24 | $129.3M | — | ||
| Q1 24 | $151.4M | — |
| Q4 25 | $147.2M | $638.1M | ||
| Q3 25 | $179.5M | — | ||
| Q2 25 | $173.2M | — | ||
| Q1 25 | $182.9M | — | ||
| Q4 24 | $171.2M | — | ||
| Q3 24 | $176.3M | — | ||
| Q2 24 | $175.7M | — | ||
| Q1 24 | $204.0M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $4.7M | $-24.8M |
| Free Cash FlowOCF − Capex | $4.1M | $-34.8M |
| FCF MarginFCF / Revenue | 6.4% | -33.5% |
| Capex IntensityCapex / Revenue | 0.9% | 9.6% |
| Cash ConversionOCF / Net Profit | 2.00× | — |
| TTM Free Cash FlowTrailing 4 quarters | $14.9M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $4.7M | $-24.8M | ||
| Q3 25 | $2.6M | — | ||
| Q2 25 | $-1.6M | — | ||
| Q1 25 | $10.8M | — | ||
| Q4 24 | $4.6M | — | ||
| Q3 24 | $5.1M | — | ||
| Q2 24 | $3.8M | — | ||
| Q1 24 | $15.9M | — |
| Q4 25 | $4.1M | $-34.8M | ||
| Q3 25 | $2.1M | — | ||
| Q2 25 | $-2.0M | — | ||
| Q1 25 | $10.7M | — | ||
| Q4 24 | $3.6M | — | ||
| Q3 24 | $3.2M | — | ||
| Q2 24 | $3.0M | — | ||
| Q1 24 | $15.0M | — |
| Q4 25 | 6.4% | -33.5% | ||
| Q3 25 | 4.0% | — | ||
| Q2 25 | -3.0% | — | ||
| Q1 25 | 18.1% | — | ||
| Q4 24 | 7.6% | — | ||
| Q3 24 | 6.5% | — | ||
| Q2 24 | 4.4% | — | ||
| Q1 24 | 21.7% | — |
| Q4 25 | 0.9% | 9.6% | ||
| Q3 25 | 0.8% | — | ||
| Q2 25 | 0.6% | — | ||
| Q1 25 | 0.2% | — | ||
| Q4 24 | 2.1% | — | ||
| Q3 24 | 3.8% | — | ||
| Q2 24 | 1.1% | — | ||
| Q1 24 | 1.3% | — |
| Q4 25 | 2.00× | — | ||
| Q3 25 | 0.97× | — | ||
| Q2 25 | -0.39× | — | ||
| Q1 25 | 4.88× | — | ||
| Q4 24 | 1.09× | — | ||
| Q3 24 | 1.51× | — | ||
| Q2 24 | 0.68× | — | ||
| Q1 24 | 3.46× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
MPX
| Boats And Accessories | $63.4M | 98% |
| Parts | $1.1M | 2% |
TWST
| Industrial Chemicals | $37.2M | 36% |
| Diagnostics | $35.3M | 34% |
| Food Or Agriculture | $12.8M | 12% |
| Academic Research | $12.2M | 12% |
| Health Care | $6.1M | 6% |
